0610010B08Rik Inhibitors
0610010B08Rik inhibitors encompass a range of chemical compounds that interact with various signaling pathways and cellular processes to reduce the functional activity of the protein. Compounds such as Staurosporine and LY294002 act as kinase inhibitors, targeting the phosphorylation events and PI3K-mediated signaling pathways, respectively, that are critical for the activation of many proteins. If 0610010B08Rik requires phosphorylation or PI3K signaling for its activity, these inhibitors would lead to its functional inhibition. Similarly, U0126 and PD98059 specifically target the MAPK/ERK pathway, which, if regulating 0610010B08Rik, would result in decreased protein function upon inhibition. Rapamycin and Bortezomib, by inhibiting mTOR and the proteasome, respectively, could suppress the synthesis or increase the stability of regulatory proteins that control 0610010B08Rik activity, thus indirectly decreasing its functional state.
Further, inhibitors like SB203580 and SP600125 interfere with stress response and JNK signaling pathways, which could be integral to the regulation of 0610010B08Rik activation. Wortmannin and MG132, both acting on PI3K and proteasomal degradation pathways, can lead to a reduction in 0610010B08Rik activity if these pathways are involved in its regulation. Imatinib and Sorafenib, both tyrosine kinase inhibitors, can dampenthe activation of 0610010B08Rik if it is influenced by tyrosine kinase signaling. By hindering the function of kinases that would normally phosphorylate or activate 0610010B08Rik, these inhibitors ensure a decrease in its activity. The specific and direct inhibition strategies employed by these chemicals ensure a targeted approach to modulating the functional state of 0610010B08Rik, by either blocking its activation signals or enhancing the stability of its negative regulators, ultimately leading to a decrease in its activity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can inhibit multiple protein kinases leading to reduced phosphorylation and activation of proteins. It can indirectly inhibit the activity of 0610010B08Rik by preventing its phosphorylation-dependent activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of PI3K which is involved in various signaling pathways, including those regulating protein activity. It can decrease the activity of 0610010B08Rik by reducing PI3K-mediated signaling events that might contribute to its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor that impedes the MAPK/ERK pathway, potentially decreasing the activation of downstream proteins such as 0610010B08Rik if it is regulated by this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that impedes the mTORC1 pathway, which could lead to a reduction in protein synthesis including the synthesis of 0610010B08Rik if it is translationally regulated by mTOR signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can block the p38 MAPK signaling pathway, potentially reducing the activity of 0610010B08Rik if it is involved in stress response signaling regulated by p38 MAPK. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An ERK pathway inhibitor that can prevent the activation of ERK1/2, possibly leading to decreased function of 0610010B08Rik if it is downstream of or regulated by ERK signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that can block PI3K-dependent signaling pathways, which could lead to decreased activity of 0610010B08Rik if it is involved in pathways dependent on PI3 kinase activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK) which may lead to the inhibition of 0610010B08Rik activity if it is part of the JNK signaling pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can decrease the degradation of inhibitory proteins that regulate the activity of other proteins, potentially leading to decreased activity of 0610010B08Rik if it is regulated by proteasomal degradation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can prevent the degradation of proteins that inhibit the activity of other proteins, potentially reducing the activity of 0610010B08Rik if it is subject to proteasomal control. | ||||||